Protective Effect of Mitochondria-Targeted Polydopamine Nanoparticles in Alleviating Hepatic Ischemia-Reperfusion Injury.

Huang Y, Cui X, You J, Xu L, Luo J, Yue P, Cao H, Cai J, Wu S, Ye Q

ACS nano30 Apr 2026

PMID42057685DOI10.1021/acsnano.5c13406PepBankPUB-42057685

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In mice with hepatic ischemia-reperfusion injury, PPS NPs significantly mitigated liver injury.
In plain wordsIn mice with liver injury, SS‑31 nanoparticles reduced liver damage.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseLiver injury
Study
mousen: not reported in source
hepatic ischemia-reperfusion injury
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Furthermore, treatment with PPS NPs significantly mitigates liver injury, decreases inflammatory factor levels, and inhibits neutrophil recruitment in mice subjected to IRI.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4205768503
02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In mice with hepatic ischemia-reperfusion injury, PPS NPs decreased inflammatory factor levels.
In plain wordsIn mice with liver injury, SS‑31 nanoparticles lowered inflammation markers.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseInflammatory factor levels
Study
mousen: not reported in source
hepatic ischemia-reperfusion injury
Outcome group
Inflammation markers · Liver
Source sentences
Summary
Furthermore, treatment with PPS NPs significantly mitigates liver injury, decreases inflammatory factor levels, and inhibits neutrophil recruitment in mice subjected to IRI.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4205768504
03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In mice with hepatic ischemia-reperfusion injury, PPS NPs inhibited neutrophil recruitment.
In plain wordsIn mice with liver injury, SS‑31 nanoparticles reduced the arrival of neutrophils in the liver.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseNeutrophil recruitment
Study
mousen: not reported in source
hepatic ischemia-reperfusion injury
Outcome group
Inflammation markers · Liver
Source sentences
Summary
Furthermore, treatment with PPS NPs significantly mitigates liver injury, decreases inflammatory factor levels, and inhibits neutrophil recruitment in mice subjected to IRI.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4205768505
04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Mechanism
In hepatic ischemia-reperfusion injury, transcriptome and metabolomics analyses indicate that PPS NPs preserved mitochondrial integrity, reduced ROS generation and regulated arachidonic acid and glutathione metabolism.
In plain wordsIn an animal liver injury model, SS‑31 nanoparticles appeared to protect mitochondria, cut harmful oxygen molecules and change two metabolic pathways.
Peptide
Elamipretide (SS-31)
Outcome
MixedMitochondrial integrity, ROS generation and arachidonic acid and glutathione metabolism
Study
n: not reported in source
hepatic ischemia-reperfusion injury
Outcome group
Mitochondrial function · Liver
Source sentences
Summary
Transcriptome sequencing and metabolomics analyses indicate that PPS NPs can protect the liver from ischemia-reperfusion injury by preserving mitochondrial integrity, reducing ROS generation, and regulating arachidonic acid and glutathione metabolism.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4205768506
05LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism
In a hypoxia/reoxygenation cell model, PPS NPs restored mitochondrial membrane potential.
In plain wordsIn cells, SS‑31 nanoparticles restored mitochondrial membrane potential after oxygen deprivation.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseMitochondrial membrane potential
Study
n: not reported in source
hypoxia/reoxygenation model
Outcome group
Mitochondrial function · Liver
Source sentences
Summary
SS-31 peptide modification confers PPS NPs with efficient mitochondrial-targeting capability, thereby restoring mitochondrial membrane potential and reducing ROS accumulation in the hypoxia/reoxygenation model.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4205768501
06LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism
In a hypoxia/reoxygenation cell model, PPS NPs reduced ROS accumulation.
In plain wordsIn cells, SS‑31 nanoparticles reduced harmful oxygen molecules after oxygen deprivation.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseROS accumulation
Study
n: not reported in source
hypoxia/reoxygenation model
Outcome group
Mitochondrial function · Liver
Source sentences
Summary
SS-31 peptide modification confers PPS NPs with efficient mitochondrial-targeting capability, thereby restoring mitochondrial membrane potential and reducing ROS accumulation in the hypoxia/reoxygenation model.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4205768502

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.